Retrospective clinicopathologic correlation of gross tumor size of hepatocellular carcinoma: Implications for stereotactic body radiotherapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 6, 2005, Pages 576-580

  Kelsey, Chris R ^a   Schefter, Tracey ^b   Nash, S Russell ^b   Russ, Paul ^b   Barón, Anna E ^b   Zeng, Chan ^b   Gaspar, Laurie E ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Clinicopathologic correlation; Hepatocellular carcinoma; Stereotactic body radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE EVALUATION; REGRESSION ANALYSIS; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGAN SIZE; PREOPERATIVE CARE; RADIOSURGERY; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 29044434319     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000184657.65679.6f     Document Type: Article

References (28)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:74 5-750.
2. Borgelt BB, Gelber R, Brady LW, et al. The palliation of hepatic metastases: results of the Radiation Therapy Oncology Group pilot study. Int J Radiat Oncol Biol Phys. 1981;7:587-591.
3. Poussin-Rosillo H, Nisce LZ, D'Angio GJ. Hepatic radiation tolerance in Hodgkin's disease patients. Radiology. 1976;121:461-464.
4. Russell AH, Clyde C, Wasserman TH, et al. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys. 1993;27:117-123.
5. Cheng SH, Lin YM, Chuang VP, et al. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 1999;14:1025-1033.
6. Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000;18:2210-2218.
7. Herfarth KK, Debus J, Lohr F, et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol. 2001;19:164-170.
8. Tokuuye K, Sumi M, Ikeda H, et al. Technical considerations for fractionated stereotactic radiotherapy of hepatocellular carcinoma. Jpn J Clin Oncol. 1997;27:170-173.
9. Herfarth KK, Debus J, Lohr F, et al. Extracranial stereotactic radiation therapy: set-up accuracy of patients treated for liver metastases. Int J Radiat Oncol Biol Phys. 2000;46:329-335.
10. Schefter T, Gaspar L, Kavanagh B, et al. Hypofractionated extracranial stereotactic radiotherapy for liver tumors. Int J Radiat Oncol Biol Phys. 2003;57:S282.
11. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
12. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8:135-160.
13. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45:255-268.
14. Fong Y, Kemeny N, Lawrence T. Cancer of the liver and biliary tree. Philadelphia: Lippincott Williams & Wilkins; 2001.
15. Dmitrewski J, El-Gazzaz G, McMaster P. Hepatocellular cancer: resection or transplantation. J Hepatobiliary Pancreat Surg. 1998;5:18-23.
16. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
17. Sangro B, Rios R, Bilbao I, et al. Efficacy and toxicity of intra-arterial cisplatin and etoposide for advanced hepatocellular carcinoma. Oncology. 2002;62:293-298.
18. Seki S, Yamada T, Kawakita N, et al. A new chemotherapeutic regimen for advanced unresectable hepatocellular carcinoma. Hepatogastroenterology. 2003;50:1598-1602.
19. Harrison LE, Koneru B, Baramipour P, et al. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg. 2003;197:759-764.
20. Hsieh CB, Chang HM, Chen TW, et al. Comparison of transcatheter arterial chemoembolization, laparoscopic radiofrequency ablation, and conservative treatment for decompensated cirrhotic patients with hepatocellular carcinoma. World J Gastroenterol. 2004;10:505-508.
21. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235-240.
22. Poon RT, Ng KK, Lam CM, et al. Effectiveness of radiofrequency ablation for hepatocellular carcinomas larger than 3 cm in diameter. Arch Surg. 2004;139:281-287.
23. Barbara L, Benzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 1992;16:132-137.
24. Gardner ES, Sumner WT, Cook JL. Predictable tissue shrinkage during frozen section histopathologic processing for Mohs micrographic surgery. Dermatol Surg. 2001;27:813-818.
25. Schned AR, Wheeler KJ, Hodorowski CA, et al. Tissue-shrinkage correction factor in the calculation of prostate cancer volume. Am J Surg Pathol. 1996;20:1501-1506.
26. Irani J, Humbert M, Lecocq B, et al. Renal tumor size: comparison between computed tomography and surgical measurements. Eur Urol. 2001;39:300-303.
27. Herr HW. Radiographic vs surgical size of renal tumours after partial nephrectomy. BJU Int. 2000;85:19-21.
28. Yaycioglu O, Rutman MP, Balasubramaniam M, et al. Clinical and pathologic tumor size in renal cell carcinoma; difference, correlation, and analysis of the influencing factors. Urology. 2002;60:33-38.